Abstract 4565
Background
With the wide introduction of anti-PD-1 agents in the treatment of NSCLC, the unusual patterns of response are now observed more frequently in the clinical setting. One of the major concerns for clinicians is hyperprogression, perceived as a reality by many but for which there is still discussion and has no standard definition. The aim of our work was to analyse the patterns of response to nivolumab in a homogeneously treated population of patients with NSCLC and identify cases with hyperprogression.
Methods
Between December 2015 and August 2017, 42 patients with NSCLC were treated with Nivolumab at 3mg/kg every 2 weeks. A retrospective evaluation of the CT scans (previous to baseline, baseline before nivolumab, subsequent scans after nivolumab) was performed by a thoracic radiologist. Tumour growth rate was defined as the percentage of variation by RECIST1.1 over time. It was calculated for the pre and post-nivolumab period (RECIST%/time (days)). We defined hyperprogressors as those patients whose tumour growth was 2 times greater on nivolumab than in the pre-nivolumab period.
Results
RECIST 1.1 evaluation was feasible in 40 patients. Best response was a partial response in 17.5% patients, including 4 cases (10%) of pseudoprogression and 2 cases with delayed response (after 1st scan). Thirty percent and 52.5% of patients showed stable disease and progressive disease, respectively. Among the 20 patients who developed progression by RECIST 1.1 on nivolumab, 16 experienced a more rapid progression in the post-nivolumab period (median % of change/t 0.6 Vs 0.3 in the pre-nivolumab period; p = 0.02)). Sixty percent (12/20) of progressing patients were hyperprogressors according to our definition (30% of the total population). No differences between hyperprogressors vs rest of progressors according to age, performance status, treatment line, gender or histology was observed.
Conclusions
Rare patterns of response (pseudoprogression, hyperprogression) must be considered in the evaluation of patients treated with immunotherapy. Unexpectedly rapid progressions are observed on immunotherapy. Standardized definitions and mechanisms for these events warrant further investigation.
Clinical trial identification
Legal entity responsible for the study
Hospital del Mar.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3816 - A prediction panel with DNA methylation biomarkers for lung adenocarcinoma
Presenter: Nan Shen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5242 - Novel genomic classifier for early stage colorectal cancer patients
Presenter: Elisabeth Letellier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5404 - Baseline Blood Immune Profiling to Predict Response to antiPD-1 in Patients with Advanced Non-Small Cell Lung Cancer
Presenter: Emanuela Romano
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5462 - Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient Mismatch Repair (pMMR) colorectal and endometrial cancers.
Presenter: Justine Cohen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5465 - Immune prognostic index (IPI) and Hyper-Progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in Phase 1 trials (Ph1T): can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?
Presenter: Ignacio Matos Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5742 - Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies
Presenter: Maria Silvia Cona
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5790 - Effects of concomitant genetic alterations on cancer patient overall survival
Presenter: Yu Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5144 - Circulating Exosomal Integrin _v_5 Predicts Liver Metastasis and Prognosis in Human Colorectal Cancer
Presenter: Dake Chu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5149 - Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for Non-Small Cell Lung Cancer patients?
Presenter: Rosalinda Sorrentino
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5673 - Smokers and COPD patients have high circulating caspase-4 levels: is it an alarm?
Presenter: Michela Terlizzi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract